In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

CHICAGO — Extended therapy with reduced-dose apixaban is just as effective as the high dose in preventing recurrent venous thromboembolism (VTE) in patients with active cancer who completed at ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

CHICAGO, IL—For patients with active cancer who’ve had venous thromboembolism (VTE), 12-month extended anticoagulation with reduced-dose apixaban is noninferior to the full dose at preventing ...

A recent study from National Taiwan University Hospital shows that apixaban, a blood-thinning medication, can help prevent blood clots in dialysis patients after a procedure to clear blocked ...

For people with HIV and atrial fibrillation (Afib or AF), certain oral anticoagulants (OACs) may carry a higher bleeding risk ...